Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes.

Schizophrenia research - 1 Feb 2018

Li Jiang, Yoshikawa Akane, Brennan Mark D, Ramsey Timothy L, Meltzer Herbert Y

Abstract excerpt

Biomarkers which predict response to atypical antipsychotic drugs (AAPDs) increases their benefit/risk ratio. We sought to identify common variants in genes which predict response to lurasidone, an AAPD, by associating genome-wide association study (GWAS) data and changes (Δ) in Positive And Negative Syndrome Scale (PANSS) scores from two 6-week randomized, placebo-controlled trials of lurasidone in schizophrenia...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Cell Adhesion Molecules

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Ion Channels

Share to Pharmacogenomic Variants

Share to Principal Component Analysis

Share to Psychiatric Status Rating Scales

Share to RNA Splicing Factors

Source

Identifiers

PMID: 28431800
DOI: 10.1016/j.schres.2017.04.009

Genes

KALRN
KCNA10
KCNK9
MAGI1
MAGI2
NBEA
NRG1
NRXN1
PTPRD
RBFOX1
SLITRK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes.PMID 28431800Read ↗

Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: A meta-analysis of samples from three independent clinical trials.Semantic proximity Read ↗

Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches.Semantic proximity Read ↗

Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study.Semantic proximity Read ↗

Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.Semantic proximity Read ↗

Genetic Markers of Early Response to Lurasidone in Acute SchizophreniaSemantic proximity Read ↗

Hot Genes in Schizophrenia: How Clinical Datasets Could Help to Refine their Role.Semantic proximity Read ↗

Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach.Semantic proximity Read ↗

Identification of novel proteins associated with movement-related adverse antipsychotic effects by integrating GWAS data and human brain proteomes.Semantic proximity Read ↗

Systems-Level Analysis of Genetic Variants Reveals Functional and Spatiotemporal Context in Treatment-resistant Schizophrenia.Semantic proximity Read ↗

Prediction of antipsychotics efficacy based on a polygenic risk score: a real-world cohort studySemantic proximity Read ↗

Toward understanding genetic risk for differential antipsychotic response in individuals with schizophreniaSemantic proximity Read ↗

Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.